keyword
MENU ▼
Read by QxMD icon Read
search

Ivabradine

keyword
https://www.readbyqxmd.com/read/28316174/-efficacy-and-safety-analysis-of-ivabradine-hydrochloride-treatment-of-chinese-patients-with-chronic-heart-failure-subgroup-analysis-of-chinese-patients-in-the-shift-study
#1
D Y Hu, D J Huang, Z Y Yuan, R P Zhao, X W Yan, M H Wang
Objective: To evaluate the efficacy and safety of ivabradine for the treatment of Chinese patients with chronic heart failure based on the Chinese subgroup data of the systolic heart failure treatment with the I(f) inhibitor ivabradine trial (SHIFT). Method: A total of 6 558 stable outpatients who presented symptoms of heart failure, with a left ventricular ejection fraction (LVEF) ≤35%, sinus rhythms with a heart rate ≥70 bpm participated in the randomized, double-blind, placebo-controlled, international multicenter clinical study...
March 24, 2017: Zhonghua Xin Xue Guan Bing za Zhi
https://www.readbyqxmd.com/read/28294866/-treatment-of-patients-with-stable-ischemic-heart-disease-in-real-clinical-practice-in-russia-the-choice-2-program
#2
G Glezer M, On Behalf Of The Choice-Study Participants On Behalf Of The Choice-Study Participants
OBJECTIVE: in the framework of an open post-marketing observational national program CHOICE-2 to assess correspondence between recommendations for management of patients with stable angina and actual clinical practice, as well as to assess effect of treatment with cytoprotector trimetazidine on clinical course of the disease. MATERIAL AND METHODS: Participating physicians (n=185 from 46 regions of Russian Federation) recruited 896 patients with ischemic heart disease (IHD)...
May 2016: Kardiologiia
https://www.readbyqxmd.com/read/28294865/-coronary-heart-disease-at-the-patient-with-metabolic-syndrome-strategy-of-antianginal-therapy
#3
N G Poteshkina, A A Troshina
Fist-line drugs in ischemic heart disease are -adrenoblockers. However there are cases when comorbidities limit possibilities of their use. In metabolic syndrome some representatives of this class unfavorably affect insulin sensitivity, carbohydrate and lipid metabolism. Alternative is to use ivabradine - selective inhibitor of If receptors with negative chronotropic activity. Ivabradine is metabolically neutral, has no negative inotropic effect, no influence on atrioventricular conduction and arterial pressure...
April 2016: Kardiologiia
https://www.readbyqxmd.com/read/28290845/-assessment-of-efficiency-of-medicamentous-therapy-in-correction-of-structurally-functional-changes-of-the-cardiac-muscle-at-patients-with-arterial-hypertension-in-combination-with-bronchial-asthma
#4
E I Tarlovskaya, A A Odegova
BACKGROUND: Bronchial asthma (BA) is a serious problem. It was found that the frequency of arterial hypertension (AH) detection in patients with asthma is about 30 %. At patients practically all types of violations of a warm rhythm meet a bronkhoobstruktivny syndrome. Emergence of rather new preparations - If-blockers, opens new opportunities in correction of heart rate (HR) and a cardioprotection at a combination of AH and BA. AIM: To assess therapy diltiazem-retard and ivabradine on structurally functional changes of a cardiac muscle and HR at patients with AH in combination with BA...
June 2016: Kardiologiia
https://www.readbyqxmd.com/read/28290829/-five-year-dynamics-of-main-clinical-symptoms-in-patients-with-ischemic-heart-disease-in-russia-in-comparison-with-other-countries-the-clarify-registry
#5
S A Shalnova, R G Oganov On Behalf Of The Participants Registry Clarify
The CLARIFY register (The prospeCtive observational LongitudinAl RegIstry oF patients with stable coronary arterY disease) combined data of outpatients with stable coronary artery disease (CAD) from 45 countries including Russia. Purpose of this publication was to analyze dynamics of stable angina during 5 years of follow up in the Russian CLARIFY cohort compared with cohorts of patients from European and non-European countries. MATERIAL AND METHODS: Number of patients recruited in Russia was 2249...
January 2017: Kardiologiia
https://www.readbyqxmd.com/read/28290813/-causes-of-angina-pectoris-in-survivors-of-myocardial-infarction-and-the-role-of-optimization-of-antianginal-therapy-data-of-the-linkor-study-e
#6
M G Glezer, E I Astashkin On Behalf Of The Linkor Study Investigators
AIM: to analyze causes of attacks of angina pectoris and assess impact of optimization of antianginal therapy on frequency of attacks provoked by various factors. MATERIAL AND METHOD: We analyzed diaries of 1226 survivors of myocardial infarction (MI) which occurred within 12months before inclusion in the LINKOR program. Causes of pain and their changes with correction of antianginal therapy were registered during 16 weeks of follow-up. RESULTS: Participants of the study indicated the following factors as causes of pain: physical exertion (74...
December 2016: Kardiologiia
https://www.readbyqxmd.com/read/28289533/ivabradine-in-the-treatment-of-systolic-heart-failure-a-systematic-review-and-meta-analysis
#7
Mahesh Anantha Narayanan, Yogesh N V Reddy, Janani Baskaran, Abhishek Deshmukh, David G Benditt, Ganesh Raveendran
AIM: To perform a systematic-review and meta-analysis to compare outcomes of ivabradine combined with beta-blocker to beta-blocker alone in heart failure with reduced ejection fraction (HFrEF). METHODS: We searched PubMed, Cochrane, EMBASE, CINAHL and Web of Science for trials comparing ivabradine + beta-blocker to beta-blocker alone in HFrEF. We performed a systematic-review and meta-analysis of published literature. Primary end-point was combined end point of cardiac death and hospitalization for heart failure...
February 26, 2017: World Journal of Cardiology
https://www.readbyqxmd.com/read/28271625/clinical-characteristics-of-patients-from-the-worldwide-registry-on-peripartum-cardiomyopathy-ppcm-eurobservational-research-programme-in-conjunction-with-the-heart-failure-association-of-the-european-society-of-cardiology-study-group-on-ppcm
#8
Karen Sliwa, Alexandre Mebazaa, Denise Hilfiker-Kleiner, Mark C Petrie, Aldo P Maggioni, Cecile Laroche, Vera Regitz-Zagrosek, Maria Schaufelberger, Luigi Tavazzi, Peter van der Meer, Jolien W Roos-Hesselink, Petar Seferovic, Karin van Spandonck-Zwarts, Amam Mbakwem, Michael Böhm, Frederic Mouquet, Burkert Pieske, Roger Hall, Piotre Ponikowski, Johann Bauersachs
AIMS: The purpose of this study is to describe disease presentation, co-morbidities, diagnosis and initial therapeutic management of patients with peripartum cardiomyopathy (PPCM) living in countries belonging to the European Society of Cardiology (ESC) vs. non-ESC countries. METHODS AND RESULTS: Out of 500 patients with PPCM entered by 31 March 2016, we report on data of the first 411 patients with completed case record forms (from 43 countries) entered into this ongoing registry...
March 8, 2017: European Journal of Heart Failure
https://www.readbyqxmd.com/read/28262346/effective-suppression-of-atrial-fibrillation-by-ivabradine-novel-target-for-an-established-drug
#9
Gerrit Frommeyer, Magdalena Sterneberg, Dirk G Dechering, Christian Ellermann, Nils Bögeholz, Simon Kochhäuser, Christian Pott, Michael Fehr, Lars Eckardt
BACKGROUND: Ivabradine is an inhibitor of mixed Na(+)-K(+)-currents and routinely administered in chronic heart failure. Clinical studies reported divergent trends regarding proarrhythmic and antiarrhythmic effects in atrial fibrillation (AF). METHODS AND RESULTS: In 12 isolated rabbit hearts AF was induced in 7 of 12 hearts (13 episodes) under baseline conditions by a standardized protocol employing atrial burst pacing. Thereafter, a combination of acetylcholine and isoproterenol was employed to enhance AF occurrence...
February 27, 2017: International Journal of Cardiology
https://www.readbyqxmd.com/read/28256323/ivabradine-in-acute-coronary-syndromes-protection-beyond-heart-rate-lowering
#10
Giampaolo Niccoli, Josip Anđelo Borovac, Vincenzo Vetrugno, Paolo G Camici, Filippo Crea
Ivabradine is a heart rate reducing agent that exhibits anti-ischemic effects through the inhibition of funny electrical current in the sinus node resulting in heart rate reduction, thus enabling longer diastolic perfusion time, and reduced myocardial oxygen consumption without detrimental changes in arterial blood pressure, coronary vasomotion, and ventricular contractility. The current guideline-based clinical use of Ivabradine is reserved for patients with stable angina pectoris who cannot tolerate or whose symptoms are inadequately controlled with beta blockers...
February 22, 2017: International Journal of Cardiology
https://www.readbyqxmd.com/read/28205056/analyzing-health-related-quality-of-life-data-to-estimate-parameters-for-cost-effectiveness-models-an-example-using-longitudinal-eq-5d-data-from-the-shift-randomized-controlled-trial
#11
Alison Griffiths, Noman Paracha, Andrew Davies, Neil Branscombe, Martin R Cowie, Mark Sculpher
INTRODUCTION: The aim of this article is to discuss methods used to analyze health-related quality of life (HRQoL) data from randomized controlled trials (RCTs) for decision analytic models. The analysis presented in this paper was used to provide HRQoL data for the ivabradine health technology assessment (HTA) submission in chronic heart failure. METHODS: We have used a large, longitudinal EuroQol five-dimension questionnaire (EQ-5D) dataset from the Systolic Heart Failure Treatment with the I f Inhibitor Ivabradine Trial (SHIFT) (clinicaltrials...
February 15, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28195070/effect-of-ivabradine-captopril-and-melatonin-on-the-behaviour-of-rats-in-l-nitro-arginine-methyl-ester-induced-hypertension
#12
S Aziriova, K Repova, K Krajcirovicova, T Baka, S Zorad, V Mojto, P Slavkovsky, J Hodosy, M Adamcova, L Paulis, F Simko
Cardiovascular diseases including hypertension are often associated with behavioural alterations. The aim of this study was to show, whether ivabradine, the blocker of If-channel in sinoatrial node, is able to modify the behaviour of rats in L-nitro-arginine methyl ester (L-NAME)-induced hypertension and to compare the effect of ivabradine with captopril and melatonin. 12-week-old male Wistar rats were divided into the following groups: controls, ivabradine (10 mg/kg/24 h), L-NAME (40 mg/kg/24 h), L-NAME + ivabradine, L-NAME + captopril (100 mg/kg/24 h), L-NAME + melatonin (10 mg/kg/24 h)...
December 2016: Journal of Physiology and Pharmacology: An Official Journal of the Polish Physiological Society
https://www.readbyqxmd.com/read/28185709/heart-failure-guidelines-what-s-new
#13
REVIEW
Lampros Papadimitriou, Carine E Hamo, Javed Butler
Heart Failure is a global epidemic, affecting approximately 5 million adults in the U.S.A. The cornerstone of contemporary pharmacological therapy targets the over activated renin-angiotensin-aldosterone and sympathetic autonomic systems. The 2016 focused pharmacologic update on the current Heart Failure Guidelines introduces the use of two newly approved regimens valsartan/sacubitril and ivabradine. Over the last two decades, guideline directed medical therapy has accomplished significant improvement in survival rates among heart failure patients; however these novel compounds were reported to exert additional mortality and morbidity benefits, in heart failure subpopulations with reduced ejection fraction...
January 11, 2017: Trends in Cardiovascular Medicine
https://www.readbyqxmd.com/read/28177679/reduced-expression-of-hcn-channels-in-sinoatrial-node-of-streptozotocin-induced-diabetic-rats
#14
Xin Huang, Nier Zhong, Hong Zhang, Aiqun Ma, Zuyi Yuan, Ning Guo
Diabetes mellitus (DM) is associated with an electrical remodeling of the heart, increasing risk of arrhythmias. However, knowledge of electrical remodeling in sinoatrial node (SAN) by DM is limited. We investigated the expression of HCN channel isoforms, HCN1-HCN4, in SAN from streptozotocin (STZ)-induced diabetic rats and the age-matched controls. We found that the STZ-induced diabetic rats have a lower intrinsic heart rate, a lengthened sinoatrial conduction time and rate-corrected maximal sinoatrial node recovery time in vivo as well as a longer cycle length (CL) in vitro as compared with the control...
December 23, 2016: Canadian Journal of Physiology and Pharmacology
https://www.readbyqxmd.com/read/28115808/the-effects-of-ivabradine-on-left-ventricular-synchronization-and-tei-index-in-patients-with-systolic-heart-failure
#15
Fatma Hizal Erdem, Serkan Ozturk, Selçuk Öztürk, Alim Erdem, Selim Ayhan, Mustafa Öztürk, İbrahim Dönmez, Davut Baltacı, Mehmet Yazıcı
BACKGROUND: The aim of our study was to evaluate in stable outpatients with systolic heart failure (HF) the 3 months effect of ivabradine on LV synchronization and Tei index in stable outpatients with systolic HF. METHODS: We evaluated prospectively 40 (30 males, 10 females) patients with HF. All patients were evaluated before and after treatment by transthoracic M mode, two dimensional (2D), pulsed-wave (PW), continuous wave (CW), color flow and tissue Doppler imaging (TDI) and tissue synchronization imaging (TSI)...
January 2017: Acta Cardiologica Sinica
https://www.readbyqxmd.com/read/27984253/does-heart-rate-really-matter-to-patients-with-heart-failure
#16
Robert J H Miller, Jonathan G Howlett
PURPOSE OF REVIEW: Measurement of heart rate (HR) and rhythm is used to identify patients at increased risk of disease progression, guide selection of treatments and gauge response to therapy. RECENT FINDINGS: Lowering HR with a pure HR lowering agent (ivabradine) in heart failure with reduced ejection fraction (HFrEF) and sinus rate more than 70 beats/min despite beta blockade has been shown to improve outcomes. Additionally, coadministration of ivabradine and beta blockade may enhance symptoms and HR control...
March 2017: Current Opinion in Cardiology
https://www.readbyqxmd.com/read/27982270/elevated-heart-rate-is-associated-with-cardiac-denervation-in-patients-with-heart-failure-a-123-iodine-mibg-myocardial-scintigraphy-study
#17
Aline Sterque Villacorta, Humberto Villacorta, Jenne Serrão de Souza, José Antônio Caldas Teixeira, Maria Clara S S S Muradas, Christiane Rodrigues Alves, Bernardo Campanário Precht, Pilar Porto, Letícia Ubaldo, Cláudio Tinoco Mesquita, Antônio Cláudio Lucas da Nóbrega
Background: In the Systolic Heart Failure Treatment With the If Inhibitor Ivabradine Trial (SHIFT), heart rate (HR) reduction with ivabradine was associated with improved survival and reduced hospitalizations in patients with heart failure (HF). The mechanisms by which elevated HR increases mortality are not fully understood. Objective: To assess the relationship of baseline HR with clinical, neurohormonal and cardiac sympathetic activity in patients with chronic HF and elevated HR...
November 2016: Arquivos Brasileiros de Cardiologia
https://www.readbyqxmd.com/read/27972043/systematic-review-of-cost-effectiveness-analysis-of-ivabradine-in-heart-failure
#18
M Dehghani, M Varmaghani, F Sharifi
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27899939/beta-blocker-use-and-risk-of-symptomatic-bradyarrhythmias-a-hospital-based-case-control-study
#19
Hou Tee Lu, Jiyen Kam, Rusli Bin Nordin, Surinder Kaur Khelae, Jing Mein Wang, Chun Ngok Choy, Chuey Yan Lee
OBJECTIVE: To investigate the risk factors of symptomatic bradyarrhythmias in relation to β-blockers use. METHODS: A hospital-based case-control study [228 patients: 108 with symptomatic bradyarrhythmias (cases) and 120 controls] was conducted in Sultanah Aminah Hospital, Malaysia between January 2011 and January 2014. RESULTS: The mean age was 61.1 ± 13.3 years with a majority of men (68.9%). Cases were likely than control to be older, hypertensive, lower body mass index and concomitant use of rate-controlling drugs (such as digoxin, verapamil, diltiazem, ivabradine or amiodarone)...
September 2016: Journal of Geriatric Cardiology: JGC
https://www.readbyqxmd.com/read/27895488/advances-in-the-management-of-heart-failure-the-role-of-ivabradine
#20
REVIEW
Ursula Müller-Werdan, Georg Stöckl, Karl Werdan
A high resting heart rate (≥70-75 b.p.m.) is a risk factor for patients with heart failure (HF) with reduced ejection fraction (EF), probably in the sense of accelerated atherosclerosis, with an increased morbidity and mortality. Beta-blockers not only reduce heart rate but also have negative inotropic and blood pressure-lowering effects, and therefore, in many patients, they cannot be given in the recommended dose. Ivabradine specifically inhibits the pacemaker current (funny current, If) of the sinoatrial node cells, resulting in therapeutic heart rate lowering without any negative inotropic and blood pressure-lowering effect...
2016: Vascular Health and Risk Management
keyword
keyword
6588
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"